These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21968319)

  • 1. Record-based, stepwise screening for type 2 diabetes integrated into an annual cardiovascular care review system: Findings from a UK general practice.
    Fisher BG; Ang YL; Goodhart C; Simmons RK
    Prim Care Diabetes; 2011 Dec; 5(4):265-9. PubMed ID: 21968319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study.
    Sargeant LA; Simmons RK; Barling RS; Butler R; Williams KM; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
    Diabet Med; 2010 Sep; 27(9):995-1003. PubMed ID: 20722672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening.
    Webb DR; Khunti K; Srinivasan B; Gray LJ; Taub N; Campbell S; Barnett J; Henson J; Hiles S; Farooqi A; Griffin SJ; Wareham NJ; Davies MJ
    Trials; 2010 Feb; 11():16. PubMed ID: 20170482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial.
    Simmons RK; Echouffo-Tcheugui JB; Sharp SJ; Sargeant LA; Williams KM; Prevost AT; Kinmonth AL; Wareham NJ; Griffin SJ
    Lancet; 2012 Nov; 380(9855):1741-8. PubMed ID: 23040422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Undetected dysglycaemia common in primary care patients treated for hypertension and/or dyslipidaemia: on the need for a screening strategy in clinical practice. A report from EUROASPIRE IV a registry from the EuroObservational Research Programme of the European Society of Cardiology.
    Shahim B; Gyberg V; De Bacquer D; Kotseva K; De Backer G; Schnell O; Tuomilehto J; Wood D; Rydén L
    Cardiovasc Diabetol; 2018 Jan; 17(1):21. PubMed ID: 29368616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Macrovascular risk and diagnostic criteria for type 2 diabetes: implications for the use of FPG and HbA(1c) for cost-effective screening.
    Jesudason DR; Dunstan K; Leong D; Wittert GA
    Diabetes Care; 2003 Feb; 26(2):485-90. PubMed ID: 12547886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of different stepwise screening strategies for type 2 diabetes: Finding from Danish general practice, Addition-DK.
    Dalsgaard EM; Christensen JO; Skriver MV; Borch-Johnsen K; Lauritzen T; Sandbaek A
    Prim Care Diabetes; 2010 Dec; 4(4):223-9. PubMed ID: 20675208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study.
    van den Donk M; Sandbaek A; Borch-Johnsen K; Lauritzen T; Simmons RK; Wareham NJ; Griffin SJ; Davies MJ; Khunti K; Rutten GE
    Diabet Med; 2011 Nov; 28(11):1416-24. PubMed ID: 21679235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for type 2 diabetes: a short report for the National Screening Committee.
    Waugh NR; Shyangdan D; Taylor-Phillips S; Suri G; Hall B
    Health Technol Assess; 2013 Aug; 17(35):1-90. PubMed ID: 23972041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of glucometer and fasting blood glucose as screening tools for diabetes mellitus type 2 and glycated haemoglobin as clinical reference in rural community primary care settings of a middle income country.
    Muktabhant B; Sanchaisuriya P; Sarakarn P; Tawityanon W; Trakulwong M; Worawat S; Schelp FP
    BMC Public Health; 2012 May; 12():349. PubMed ID: 22583817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of glycated hemoglobin in screening and diagnosing type 2 diabetes mellitus in Chinese subjects.
    Yu Y; Ouyang XJ; Lou QL; Gu LB; Mo YZ; Ko GT; Chow CC; So WY; Ma R; Kong A; Brown N; Nan J; Chan J; Bian RW
    Korean J Intern Med; 2012 Mar; 27(1):41-6. PubMed ID: 22403498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the potential population impact of stepwise screening strategies for identifying and treating individuals at high risk of Type 2 diabetes: a modelling study.
    Chamnan P; Simmons RK; Khaw KT; Wareham NJ; Griffin SJ
    Diabet Med; 2012 Jul; 29(7):893-904. PubMed ID: 22340130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms.
    Christensen JO; Sandbaek A; Lauritzen T; Borch-Johnsen K
    Diabetologia; 2004 Sep; 47(9):1566-73. PubMed ID: 15365615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for type 2 diabetes with random finger-prick glucose and bedside HbA1c in an Australian emergency department.
    Jelinek GA; Weiland TJ; Moore G; Tan G; Maslin M; Bowman K; Ward G; O'Dea K
    Emerg Med Australas; 2010 Oct; 22(5):427-34. PubMed ID: 21040483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of HbA(1c) in screening for Cuban-Americans with undiagnosed type 2 diabetes.
    Huffman FG; Exebio JC; Zarini GG; Exebio C
    J Immigr Minor Health; 2011 Jun; 13(3):541-5. PubMed ID: 20577810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Random blood glucose: a robust risk factor for type 2 diabetes.
    Bowen ME; Xuan L; Lingvay I; Halm EA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1503-10. PubMed ID: 25650899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus.
    Schöttker B; Müller H; Rothenbacher D; Brenner H
    Diabetologia; 2013 Jan; 56(1):92-100. PubMed ID: 22986731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of haemoglobin A1c and fasting plasma glucose for incident diabetes and implications for screening.
    Schöttker B; Raum E; Rothenbacher D; Müller H; Brenner H
    Eur J Epidemiol; 2011 Oct; 26(10):779-87. PubMed ID: 21947790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults.
    Simmons RK; Griffin SJ; Witte DR; Borch-Johnsen K; Lauritzen T; Sandbæk A
    Diabetologia; 2017 Nov; 60(11):2183-2191. PubMed ID: 28831535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon Hospital Health Management Center Study 6 (TOPICS 6).
    Heianza Y; Arase Y; Hsieh SD; Saito K; Tsuji H; Kodama S; Tanaka S; Ohashi Y; Shimano H; Yamada N; Hara S; Sone H
    Diabetologia; 2012 Dec; 55(12):3213-23. PubMed ID: 22955996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.